The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CELC | +375.2% | +1,180.53% | +66.52% | +426% |
| S&P | +18.54% | +92.9% | +14.04% | +170% |
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.04M | -28.6% |
| Market Cap | $505.52M | -12.1% |
| Market Cap / Employee | $5.81M | 0.0% |
| Employees | 87 | 58.2% |
| Net Income | -$45.27M | -90.8% |
| EBITDA | -$43.97M | -81.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $46.35M | 52.2% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $99.28M | 3.1% |
| Short Term Debt | $0.14M | -22.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -62.47% | -25.4% |
| Return On Invested Capital | -45.66% | -2.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$36.29M | -100.2% |
| Operating Free Cash Flow | -$36.25M | -100.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.12 | 3.25 | 3.25 | 5.83 | 54.64% |
| Price to Tangible Book Value | 3.12 | 3.25 | 3.25 | 5.83 | 54.64% |
| Enterprise Value to EBITDA | -15.69 | -11.65 | -9.09 | -11.69 | -36.03% |
| Return on Equity | -77.5% | -87.5% | -115.4% | -134.5% | 133.63% |
| Total Debt | $97.19M | $97.95M | $98.71M | $99.42M | 3.01% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
